Cutting-Edge Research at the Service of Your Well-Being
At the SAGA Clinical Studies Center, we combine world-class science with human care. We are a leading institution in Chile dedicated to bringing the treatments of the future for metabolic diseases to the country.
What does this mean for you?
It means that, through clinical research, our patients gain access to innovative therapeutic alternatives, first-rate medical monitoring, and the opportunity to contribute to the advancement of global medicine.
Our Areas of Specialization
If you live with any of the following conditions, at SAGA we are working to transform their treatment:
- Obesity and Overweight.
- Prediabetes, Type 1 and Type 2 Diabetes.
- Liver Diseases (Fatty Liver and others).
- Cardiovascular Diseases.
- Chronic Kidney Disease.
- Sleep Apnea.
- Sarcopenia and Body Composition.
- Joint Pain.
Medical Leadership: Science, Nationwide Coverage, and Commitment
The area is under the direction of Dr. Isabela Morales Pillon, Principal Investigator and physician specialized in Nutrology (ABRAN) and Obesity (SCOPE, World Obesity Federation).
Dr. Morales Pillon brings a binational clinical architecture, with an active career in Brazil and Chile, in addition to serving as Medical Director of an international hub with an in-person site in Las Condes and a telemedicine platform with coverage throughout Chile. This makes it possible to offer specialized evaluation, longitudinal follow-up, and programs with nationwide reach, leading a team that works under the highest standards of quality, safety, and a human, patient-centered approach.
Would You Like to Be Part of a Clinical Study?
Participating in a study is a voluntary act that helps millions of people. At SAGA, we ensure that every participant is treated under the strictest ethical and international safety protocols.
Information for Institutions and Sponsors
SAGA is a well-established reference in Chile with 85 awarded contracts and recognition as a 4-time Global Top Enroller. Our infrastructure is designed to exceed industry standards:
Recruitment Capacity
Chile is today one of the countries with the highest metabolic burden in the world, which represents a direct operational advantage for accelerated recruitment. According to the World Obesity Atlas, 42% of adults live with obesity and about 83% have an elevated BMI. According to the IDF Diabetes Atlas, Chile has approximately 1.86 million adults with diabetes, an adjusted prevalence of 12.2%, and 17% of cases without a prior diagnosis, a high-value population for early intervention protocols. SAGA capitalizes on this context through a network of 35 hospitals coordinated nationwide and a telemedicine platform operating throughout Chile, ensuring a constant, qualified, multilayered patient funnel under active binational medical leadership in Brazil and Chile.
Startup and Regulatory
Proven track record of First Patient In within the first month after the green light. Efficient ethics approval processes, centralized document management, and a direct interface with the sponsor and CRO in all phases of the protocol.
Data Quality
Focus on Audit Readiness from day 1, aimed at an accelerated Database Lock and strict compliance with ICH-GCP E6 R3. The PI holds GCP certification with an excellence score of 95%. Agile query resolution and high-standard document traceability.
Therapeutic Focus
Our Metabolic Area specializes in Phase I to IV protocols with a focus on next-generation incretin-based molecules. Complex clinical programs with highly demanding metabolic, hepatic, renal, and cardiovascular endpoints. Our operational capacity covers the full spectrum of high-demand indications:
Obesity and Overweight: Protocols in populations with a BMI of 30 or higher, with and without associated T2DM. Endpoints for body composition, fat mass reduction, lean mass preservation, and long-term weight maintenance.
Type 1 and Type 2 Diabetes Mellitus: Glycemic optimization, HbA1c reduction, and prevention of progression from prediabetes. Management of micro- and macrovascular endpoints, including major cardiovascular events and cardiovascular mortality.
Metabolic Liver Disease and CKD: Protocols in MASLD/MASH with and without advanced fibrosis and in Chronic Kidney Disease of metabolic origin. Capacity for histological endpoints and non-invasive fibrosis biomarkers.
Cardiometabolic Risk: Prevention of major cardiovascular events in obese populations without T2DM. Endpoints in heart failure with preserved ejection fraction, hospitalization for HF, and functional capacity.
Systemic Complications of Excess Weight: Obstructive Sleep Apnea with endpoints of apnea-hypopnea index and sleep architecture. Sarcopenia with measurement of muscle mass, strength, and gait speed. Knee osteoarthritis with assessment of mechanical load and inflammatory biomarkers.
Are you looking for a high-performance site for your next metabolic protocol? Access predictable recruitment and operational excellence in Chile
